The coBRIM trial compared the combination of vemurafenib and cobimetinib fumarate (BRAF and MEK inhibitors) with vemurafenib monotherapy for the treatment of BRAF V600–positive advanced melanoma and led to the approval of this combination in 2015 as well.38 The median PFS was better with the combination treatment (12.3 vs 7.2 months). The gene discussed is MAP2K7; the disease is melanoma.